We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences Corp. (EXAS - Free Report) recently announced preliminary revenue results for fourth quarter and full-year 2019. The company is slated to release detailed financial results for the same period in February.
Following the release, the stock lost 0.3% reaching $79.36 at the close of trading on Jan 16.
For the to-be-reported quarter, Exact Sciences expects total revenues within $294-$296 million. Notably, the Zacks Consensus Estimate for the same is currently pegged at $295.7 million.
For the year, total revenues are expected in the band of $874.5-$876.5 million, per the preliminary announcement. This is higher than the company’s earlier guidance of $802-$810 million as well as the Zacks Consensus Estimate of $808.7 million.
For 2019, total revenues are likely to have risen substantially on expectation of growth in Cologuard and Oncotype DX (two of the company’s strongest brands in cancer diagnostics and testing). Also, Screening (revenues from Cologuard and Biomatrica products) and Precision Oncology (global Oncotype DX product) proforma revenues are projected to see strong growth.
Latest Q4 Projections
Cologuard and Oncotype DX are expected to have performed impressively in the to-be-reported quarter with volume increases of 477,000 (up 63%) and 41,000 (up 14%) respectively.
For the quarter, Screening revenues are likely to be around $229-$230 million, indicating an increase of 61% year over year.
Precision Oncology revenues for the period between Nov 8 and Dec 31, 2019 are likely to be $65-$66 million, following the completion of the Genomic Health acquisition. Precision Oncology proforma revenues for the full fourth quarter are expected within $118-$119 million (suggesting 13% rise), provided the Genomic Health buyout is the only driving factor.
Price Performance
Shares of Exact Sciences have gained 13.9% in the past year against the industry’s 2.8% fall.
Zacks Rank & Other Key Picks
Currently, the company carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , Hill-Rom Holdings, Inc. and Medtronic plc (MDT - Free Report) .
Hill-Rom’s long-term earnings growth rate is estimated at 11.7%. The company presently carries a Zacks Rank #2.
Medtronic’s long-term earnings growth rate is estimated at 7.4%. It currently carries a Zacks Rank #2.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
Exact Sciences Corp. (EXAS - Free Report) recently announced preliminary revenue results for fourth quarter and full-year 2019. The company is slated to release detailed financial results for the same period in February.
Following the release, the stock lost 0.3% reaching $79.36 at the close of trading on Jan 16.
For the to-be-reported quarter, Exact Sciences expects total revenues within $294-$296 million. Notably, the Zacks Consensus Estimate for the same is currently pegged at $295.7 million.
For the year, total revenues are expected in the band of $874.5-$876.5 million, per the preliminary announcement. This is higher than the company’s earlier guidance of $802-$810 million as well as the Zacks Consensus Estimate of $808.7 million.
For 2019, total revenues are likely to have risen substantially on expectation of growth in Cologuard and Oncotype DX (two of the company’s strongest brands in cancer diagnostics and testing). Also, Screening (revenues from Cologuard and Biomatrica products) and Precision Oncology (global Oncotype DX product) proforma revenues are projected to see strong growth.
Latest Q4 Projections
Cologuard and Oncotype DX are expected to have performed impressively in the to-be-reported quarter with volume increases of 477,000 (up 63%) and 41,000 (up 14%) respectively.
For the quarter, Screening revenues are likely to be around $229-$230 million, indicating an increase of 61% year over year.
Precision Oncology revenues for the period between Nov 8 and Dec 31, 2019 are likely to be $65-$66 million, following the completion of the Genomic Health acquisition. Precision Oncology proforma revenues for the full fourth quarter are expected within $118-$119 million (suggesting 13% rise), provided the Genomic Health buyout is the only driving factor.
Price Performance
Shares of Exact Sciences have gained 13.9% in the past year against the industry’s 2.8% fall.
Zacks Rank & Other Key Picks
Currently, the company carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , Hill-Rom Holdings, Inc. and Medtronic plc (MDT - Free Report) .
Haemonetics, currently flaunting a Zacks Rank #1 (Strong Buy), has a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hill-Rom’s long-term earnings growth rate is estimated at 11.7%. The company presently carries a Zacks Rank #2.
Medtronic’s long-term earnings growth rate is estimated at 7.4%. It currently carries a Zacks Rank #2.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>